PT  - JOURNAL ARTICLE
AU  - Henderson, John
AU  - Mantso, Theodora
AU  - Ali, Saqib
AU  - Groß, Rüdiger
AU  - Müller, Janis A.
AU  - Wilkinson, Amie
AU  - Shah, Kavit
AU  - Usher, Louise
AU  - Auld, Beth
AU  - Nelson, Andrew
AU  - Cheung, William
AU  - Namdeo, Anil
AU  - Combrinck, Madeleine
AU  - Hackney, Phil
AU  - Turgul, Volkan
AU  - Jahaj, Edison
AU  - Athanasiou, Nikolaos
AU  - Nikolouzakis, Taxiarchis
AU  - Almeida, Pedro J.
AU  - Rokka, Chrysa
AU  - Queiroz, Daniel C.
AU  - Wright, Edward
AU  - Zafiropoulos, Alexandros
AU  - Kale, Izzet
AU  - Smith, Darren
AU  - Kofteridis, Diamantis P.
AU  - Tsatsakis, Aristides
AU  - Münch, Jan
AU  - Katsaounou, Paraskevi A.
AU  - Kotanidou, Anastasia
AU  - Lagiou, Pagona
AU  - Magiorkinis, Gkikas
AU  - Aquiar, Renato S
AU  - Teixeira, Mauro M.
AU  - Moschos, Sterghios A.
TI  - Airborne Pathogen Detection in Fine Aerosol Exhaled Breath Condensates
AID  - 10.1101/2022.05.25.22275435
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.25.22275435
4099  - http://medrxiv.org/content/early/2022/09/05/2022.05.25.22275435.short
4100  - http://medrxiv.org/content/early/2022/09/05/2022.05.25.22275435.full
AB  - Rationale Exhaled breath condensate (EBC) promises a valuable, non-invasive, and easy to obtain clinical sample. However, it’s not currently used diagnostically due to poor reproducibility, sample contamination, and sample loss.Objective We evaluated whether a new, hand-held EBC collector (PBM-HALETM) that separates inertially impacted large droplets (LD) before condensing fine aerosols (FA) in distinct, self-sealing containers, overcomes current limitations.Methods Sampling consistency was determined in healthy volunteers by microbial culture, 16S phylogenetics, spectrophotometry, RT-PCR, and HILIC-MS. Capture of aerosolised polystyrene beads, liposomes, virus-like particles, or pseudotyped virus was analysed by nanoparticle tracking analysis, reporter expression assays, and flow cytometry. Acute symptomatic COVID-19 case tidal FA EBC viral load was quantified by RT-qPCR. Exhaled particles were counted by laser light scattering.Measurements and Main Results Salivary amylase-free FA EBC capture was linear (R2=0.9992; 0.25-30 min) yielding RNA (6.03 μg/mL) containing eukaryotic 18S rRNA (RT-qPCR; p<0.001) but not human GAPDH, RNase P, or beta actin mRNA;141 non-volatile metabolites included eukaryotic cell membrane components, and cuscohygrine 3 days after cocaine abuse. Culturable aerobe viability was condensation temperature-dependent. Breath fraction-specific microbiota were stable, identifying Streptococcus enrichment in a mild dry cough case. Nebulized pseudotyped virus infectivity loss <67% depended on condensation temperature, and particle charge-driven aggregation. SARS-CoV-2 RNA genomes were detected only by forced expiration FA EBC capture, in 100% of acute COVID-19 patients.Conclusions High purity, distal airway FA EBC can reproducibly and robustly inform contamination-free infectious agent emission sources, and be quantitatively assayed for multiple host, microbial, and lifestyle biomarker classes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the InnovateUK iCURE III project no. 43055, and the Northern Accelerator II project no. 25R18P02557. JAM received funding from the German Research Foundation. Airborne particle size analysis was enabled by the kind loan of equipment by Particles Plus Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All healthy volunteer EBC samples used within this study were obtained with participant informed consent under Northumbria University ethics application no. 43341 approved by the Department of Applied Sciences Subcommittee of University Research Ethics Committee. All COVID-19 patient EBC samples were collected under informed consent under the National and Kapodistrian University of Athens General Hospital Evangelismos ethics application protocol no. 280/24-4-2020 approved by the Scientific Committee of the General Hospital Evangelismos, and approval no. 54358021.1.0000.5149 fy the Institutional Review Board of the Federal University of Minas GeraisI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors